Literature DB >> 8083686

Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease.

A D Roses1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8083686     DOI： 10.1097/00005072-199409000-00002

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN： 0022-3069            Impact factor:   3.685


× No keyword cloud information.
  57 in total

Review 1.  Science, medicine, and the future: Postgenomic technologies: hunting the genes for common disorders.

Authors:  C Mathew
Journal:  BMJ       Date:  2001-04-28

2.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

Authors:  Y Huang; X Q Liu; T Wyss-Coray; W J Brecht; D A Sanan; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

Authors:  Shengjun Chang; Tian ran Ma; R Dennis Miranda; Maureen E Balestra; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

5.  Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent.

Authors:  A Salehi; E J Dubelaar; M Mulder; D F Swaab
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

6.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Authors:  Cathleen D Zick; Charles J Mathews; J Scott Roberts; Robert Cook-Deegan; Robert J Pokorski; Robert C Green
Journal:  Health Aff (Millwood)       Date:  2005 Mar-Apr       Impact factor: 6.301

7.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

Review 8.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

10.  Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice.

Authors:  Faith M Harris; Walter J Brecht; Qin Xu; Ina Tesseur; Lisa Kekonius; Tony Wyss-Coray; Jo Dee Fish; Eliezer Masliah; Paul C Hopkins; Kimberly Scearce-Levie; Karl H Weisgraber; Lennart Mucke; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-25       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.